Compare GOOD & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOOD | ZVRA |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.0M | 502.7M |
| IPO Year | N/A | 2015 |
| Metric | GOOD | ZVRA |
|---|---|---|
| Price | $11.72 | $8.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $11.00 | ★ $21.71 |
| AVG Volume (30 Days) | 487.3K | ★ 952.8K |
| Earning Date | 02-18-2026 | 03-10-2026 |
| Dividend Yield | ★ 10.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.18 | ★ 0.54 |
| Revenue | ★ $155,250,000.00 | $84,388,000.00 |
| Revenue This Year | $8.62 | $333.64 |
| Revenue Next Year | $6.28 | $43.58 |
| P/E Ratio | $63.94 | ★ $16.62 |
| Revenue Growth | 4.95 | ★ 244.60 |
| 52 Week Low | $10.33 | $6.19 |
| 52 Week High | $16.63 | $13.16 |
| Indicator | GOOD | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 74.08 | 54.49 |
| Support Level | $11.13 | $8.08 |
| Resistance Level | $11.40 | $9.24 |
| Average True Range (ATR) | 0.21 | 0.41 |
| MACD | 0.11 | 0.08 |
| Stochastic Oscillator | 98.02 | 73.28 |
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.